SRR1797283
— · cohortSC
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSC
- subtype
- cohortSC
- age_years
- 44
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.460
- MYC_TARGETS_V1+0.460
- G2M_CHECKPOINT+0.420
- MITOTIC_SPINDLE+0.330
- DNA_REPAIR+0.320
- PROTEIN_SECRETION+0.240
- MYC_TARGETS_V2+0.230
- OXIDATIVE_PHOSPHORYLATION+0.220
- PEROXISOME+0.210
- SPERMATOGENESIS+0.180
Top 10 suppressed
- ANGIOGENESIS-0.520
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.470
- INFLAMMATORY_RESPONSE-0.460
- TNFA_SIGNALING_VIA_NFKB-0.430
- IL6_JAK_STAT3_SIGNALING-0.400
- COAGULATION-0.380
- MYOGENESIS-0.370
- ALLOGRAFT_REJECTION-0.350
- APICAL_SURFACE-0.340
- IL2_STAT5_SIGNALING-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_1HQ76V6D | Embryonal tumors | — | 0.936 |
| 2 | MDT-AP-0188 | Med | Medulloblastoma | 0.931 |
| 3 | SRR1797245 | — | cohortSC | 0.927 |
| 4 | BS_HKZENFDA | medulloblastoma | — | 0.927 |
| 5 | 236350e9-8964-42ae-8880-d2f2281ff993 | — | — | 0.924 |
| 6 | SRR1797285 | — | cohortSC | 0.923 |
| 7 | MDT-AP-2917 | Med | Medulloblastoma | 0.923 |
| 8 | 7DC6D598-8506-4680-81DF-C1D0F1B5C27D | — | — | 0.920 |
| 9 | BS_TV5B86ZD | Embryonal tumors | — | 0.920 |
| 10 | BS_8QB4S4VA | Embryonal tumors | — | 0.919 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.460 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.420 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.330 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.320 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.240 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.230 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.220 | Remibrutinib | — uncovered |
| PEROXISOME | 0.210 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.090 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.090 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.080 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.060 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.020 | Cobimetinib | — uncovered |
| ADIPOGENESIS | 0.010 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |